98%
921
2 minutes
20
Background: HIV-1 controllers are a rare population of individuals that exhibit spontaneous control of HIV-1 infection without antiretroviral therapy. Understanding the mechanisms by which HIV-1 controllers maintain and eventually lose this ability would be highly valuable in HIV-1 cure or vaccine research. Previous work revealed the ability of CD8+ T cells isolated from HIV-1 controllers to suppress HIV-1 replication in matched CD4+ T cells and PBMCs ex vivo and suggested the loss of control may be tied to CD8+ T cell exhaustion.
Results: We explored whether CD8+ T cell exhaustion plays a role in the maintenance and loss of control by examining immune characteristics of HIV-1 persistent controllers and transient controllers who lost control within the duration of the study. Using flow cytometry, we analyzed exhaustion marker expression on CD8+ T cells from HIV-1 controllers and determined that they maintain a unique exhaustion profile as compared to people without HIV-1 and HIV-1 standard progressors. The low level of T cell exhaustion seen in HIV-1 controllers was reversed when these individuals lost control and showed increased viral loads. Combinatorial immune checkpoint blockade targeting exhaustion markers was able to restore ex vivo control in CD8+ T cells from former controllers.
Conclusions: These results suggest that CD8+ T cell exhaustion compromises the ability to control viral replication in HIV-1 controllers. The character of exhaustion in response to HIV-1 and therapy is distinct in HIV-1 persistent controllers, transient controllers and standard progressors.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12393755 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0328706 | PLOS |
PLoS Pathog
September 2025
INSERM UMR 1291, CNRS UMR 5051, Université de Toulouse, Toulouse Institute for Infectious and Inflammatory Diseases, Toulouse, France.
Vδ1 γδ T cells are key players in innate and adaptive immunity, particularly at mucosal interfaces such as the gut. An increase in circulating Vδ1 cells has long been observed in people with HIV-1, but remains poorly understood. We performed a comprehensive characterization of Vδ1 T cells in blood and duodenal intra-epithelial lymphocytes, obtained from endoscopic mucosal biopsies of 15 people with HIV-1 on antiretroviral therapy and 15 HIV-seronegative controls, in a substudy of the ANRS EP61 GALT study (NCT02906137).
View Article and Find Full Text PDFCell Tissue Bank
September 2025
Eurofins Donor & Product Testing, LLC, Centennial, CO, USA.
In the United States, the use of Food & Drug Administration (FDA)-licensed, approved, or cleared tests is required for infectious disease screening and determining the eligibility of deceased donors for all Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). With the discontinuation of two manual enzyme-linked immunoassay (EIA) tests, automated Chemiluminescent Microparticle Immunoassay (CMIA) technology was introduced as the primary alternative. This study compares serologic reactivity rates between manual EIA and automated CMIA methods.
View Article and Find Full Text PDFCurr HIV Res
August 2025
U.S. Mil-itary HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Reports of HIV-1-specific broadly neutralizing monoclonal antibodies (bNAbs) medi-ating a potential 'vaccinal effect' implicate passively transferred bNAbs in promoting endoge-nous anti-HIV-1 immune responses. To date, three clinical trials have reported either increased anti-HIV-1 neutralizing antibodies or T cell responses following bNAb administration to people living with HIV. Despite strong enthusiasm for this hypothesis, motivated in large part by its potential application to HIV-1 therapeutic strategies, the mechanism(s) underlying a vaccinal ef-fect remain unclear.
View Article and Find Full Text PDFHIV Med
September 2025
Department of Medical Microbiology, Faculty of Medicine, Hacettepe University, Ankara, Türkiye.
Introduction: Monitoring transmitted drug resistance is crucial for guiding first-line antiretroviral therapy (ART) and controlling the rising HIV epidemic in Türkiye. This study aimed to determine the prevalence of transmitted antiretroviral resistance to protease inhibitors (PIs), nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase strand transfer inhibitors (INSTIs) and capsid assembly inhibitors (CAIs). We also assessed the distribution of HIV-1 subtypes and circulating recombinant forms (CRFs) at one of the main national referral centres in Türkiye.
View Article and Find Full Text PDFAnal Chim Acta
November 2025
HIV-1 Molecular Epidemiology Laboratory, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Microbiology Department, Hospital Universitario Ramón y Cajal, CIBER en Epidemiología y Salud Pública (CIBERESP), Madrid, 28034, Spain. Electronic address:
Background: Currently, 39.9 million people are infected with the human immunodeficiency virus (HIV), and 1.3 million new infections occur annually, with over 170 circulating variants.
View Article and Find Full Text PDF